Study authors gathered data on patients who underwent the injections from June 2012 to July 2013 with EuroQOL-5D scores taken before and after the intervention. There were 323 patients who participated in the study.
Study authors found:
1. The average cost per injection was $608 for patients who received three injections over more than one year.
2. Average quality-adjusted life year gained was 0.005, with 45 percent reporting 0.117 QALY gained at a cost of $62,175 per QALY gained.
3. Around 127 patients, or 40 percent, reported a loss in QALY while another 15 percent reported no change.
4. There were 145 patients who improved and 178 patients who did improve; 14 of the patients who did improve and 29 of those who did not reported medical comorbidities before surgery.
5. The study showed injections may not be cost-effective for lumbar degenerative disorders, although study authors recommended further studies may identify specific patient populations who could benefit from the injections.
More articles on spine surgery:
4 trends spine surgeons can expect—Dr. Harel Deutsch on the industry’s direction
10 spine surgeon leaders to know
5 things to know about spine surgery volume benchmarks: What is the cut-point for high quality?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
